Trial Profile
An Evaluation of Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 19 Aug 2020
Price :
$35
*
At a glance
- Drugs Brexanolone (Primary)
- Indications Major depressive disorder; Postnatal depression
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Sage Therapeutics
- 14 Aug 2020 Status changed from not yet recruiting to withdrawn prior to enrolment as Sage Therapeutics has decided not to proceed with this study at this time
- 20 Feb 2020 New trial record